Please wait a minute...
文章检索
预防医学  2023, Vol. 35 Issue (4): 339-341    DOI: 10.19485/j.cnki.issn2096-5087.2023.04.016
  疾病监测 本期目录 | 过刊浏览 | 高级检索 |
湖州市疫苗接种相关的过敏性皮疹监测结果
钱晓萍1, 罗小福2, 凌健1
1.湖州市吴兴区疾病预防控制中心免疫规划科,浙江 湖州 313000;
2.湖州市疾病预防控制中心,浙江 湖州 313000
Surveillance on allergic rash associated with vaccination in Huzhou City
QIAN Xiaoping1, LUO Xiaofu2, LING Jian1
1. Department of Immunization Planning, Wuxing Center for Disease Control and Prevention, Huzhou, Zhejiang 313000, China;
2. Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang 313000, China
全文: PDF(820 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析2017—2021年浙江省湖州市疫苗接种相关的过敏性皮疹监测结果,为防制过敏性皮疹提供依据。方法 通过中国疾病预防控制信息系统疑似预防接种异常反应(AEFI)监测管理模块收集2017—2021年湖州市疫苗接种相关的过敏性皮疹病例资料,描述性分析过敏性皮疹的流行特征、接种疫苗分布和临床表现。结果 2017—2021年湖州市累计报告过敏性皮疹324例,年均报告发生率为6.12/10万剂,其中男性为6.40/10万剂,女性为5.82/10万剂;年龄以<1岁为主,报告发生率为8.32/10万剂。各季度中以第二季度报告例数最多,108例占33.33%。各县(区)中以德清县报告例数最多,92例占28.40%,报告发生率为11.52/10万剂。麻疹风疹联合减毒活疫苗报告发生率最高,为41.23/10万剂。临床诊断为过敏性皮疹203例,占62.65%;荨麻疹55例,占16.98%;麻疹猩红热样皮疹51例,占15.74%;斑丘疹15例,占4.63%。发热94例,占29.01%。78.70%的过敏性皮疹发生在接种后24 h内。结论 2017—2021年湖州市疫苗接种相关的过敏性皮疹发生率较高,多发生于首剂疫苗接种后24 h内,以1岁以下儿童高发。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
钱晓萍
罗小福
凌健
关键词 过敏性皮疹预防接种疑似预防接种异常反应    
AbstractObjective To investigate the incidence of allergic rash associated with vaccination in Huzhou City from 2017 to 2021, so as to provide insights into the prevention and control of allergic rash. Methods Data pertaining to cases with vaccination-related allergic rash in Huzhou City from 2017 to 2021 were captured from the National Adverse Events Following Immunization Surveillance System of Chinese Disease Control and Prevention Information System, and epidemiological characteristics, vaccination and clinical features of allergic rash were analyzed. Results Totally 324 allergic rash cases were reported in Huzhou City from 2017 to 2021, with an annual reported incidence of 6.12/105 doses. The incidence of allergic rash was 6.40/105 doses among men and 5.82/105 doses among women, and allergic rash predominantly occurred among cases under 1 year, with a reported incidence of 8.32/105 doses. The largest number of cases was reported in the second quarter (108 cases, 33.33%), and the largest number of cases was reported in Deqing County (92 cases, 28.40%) with a reported incidence of 11.52/105 doses. The highest reported incidence of allergic rash was seen following immunization with combined live-attenuated measles-mumps-rubella vaccines (41.23/105 doses). There were 203 cases (62.65%) diagnosed as allergic rash, 55 cases (16.98%) diagnosed as urticaria, 51 cases (15.74%) diagnosed as measles scarlet fever-like rash, and 15 cases (4.63%) diagnosed as maculopapule. There were 94 (29.01%) cases with fever, and 78.70% allergic rash occurred within 24 hours of vaccination. Conclusion The incidence of allergic rash associated with vaccination was high in Huzhou City from 2017 to 2021, and vaccination-related allergic rash predominantly occurred within 24 hours following immunization with the first dose of vaccines. Allergic rash associated with vaccination was highly prevalent among children under 1 year.
Key wordsallergic rash    vaccination    adverse events following immunization
收稿日期: 2023-01-18      修回日期: 2023-03-04      出版日期: 2023-04-10
中图分类号:  R186  
作者简介: 钱晓萍,本科,副主任医师,主要从事免疫规划和传染病控制工作
引用本文:   
钱晓萍, 罗小福, 凌健. 湖州市疫苗接种相关的过敏性皮疹监测结果[J]. 预防医学, 2023, 35(4): 339-341.
QIAN Xiaoping, LUO Xiaofu, LING Jian. Surveillance on allergic rash associated with vaccination in Huzhou City. Preventive Medicine, 2023, 35(4): 339-341.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.04.016      或      http://www.zjyfyxzz.com/CN/Y2023/V35/I4/339
[1] 中华人民共和国卫生部办公厅,国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[S].2010.
[2] 杨宏,王华庆.中国2008—2012年预防接种后过敏性皮疹监测分析[J].中国疫苗和免疫,2014,20(2):19-25.
[3] 张丽娜,李克莉,李燕,等.2020年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2022,28(4):208-218.
[4] 潘雪娇,李倩,戚小华,等.浙江省2013—2014年疑似预防接种异常反应监测数据分析[J].浙江预防医学,2015,27(11):1128-1130.
[5] 王晓柳,汤元妃.2018—2021年武义县疑似预防接种异常反应监测结果[J].预防医学,2022,34(11):1167-1171.
[6] 严波,周倩意,郑晓晖,等.中国儿童家长疑似预防接种异常反应知晓率的Meta分析[J].预防医学,2021,33(3):250-254.
[7] 吉赛赛,李克莉,武文娣,等.2015—2016年中国疑似预防接种异常反应的季节性特征[J].中国疫苗和免疫,2018,24(2):193-201.
[8] 常琳,孙静,方兴.季节性ARIMA模型在疑似预防接种异常反应报告趋势预测中的应用[J].中国卫生统计,2021,38(2):241-242,246.
[9] 方峰. 儿童疫苗接种常见不良反应及处理[J].中国实用儿科杂志,2016,31(5):336-340.
[10] 张超,沈建勇,罗小福,等.2015—2021年湖州市MMR疫苗疑似预防接种异常反应监测结果[J].预防医学,2023,35(1):74-77.
[11] 杜哲群,胡洁,沈国初,等.嘉兴市8月龄儿童接种MMR、MR疫苗疑似预防接种异常反应监测结果[J].预防医学,2020,32(11):1086-1090.
[12] DEMOLY P,ADKINSON N F,BROCKOW K,et al.International consensus on drug allergy[J].Allergy,2014,69(4):420-437.
[1] 张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
[2] 王炸亚, 叶莉霞, 吴锋. 宁波市2018—2021年出生儿童肠道病毒71型疫苗接种情况分析[J]. 预防医学, 2023, 35(10): 895-898.
[3] 何飞, 马永法, 顾春艳, 潘铭, 陈万庚. 2005—2021年盐都区水痘流行特征[J]. 预防医学, 2023, 35(1): 61-64.
[4] 江伟, 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 顾雯雯, 张小平. 2017—2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73,77.
[5] 张超, 沈建勇, 罗小福, 徐秦儿, 韩利萍. 2015—2021年湖州市MMR疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 74-77.
[6] 龚震宇, 龚训良. 全球消除脊髓灰质炎进展[J]. 预防医学, 2022, 34(8): 861-862.
[7] . 系统性红斑狼疮患者疫苗接种专家共识[J]. 预防医学, 2022, 34(12): 1189-1193.
[8] 王晓柳, 汤元妃. 2018—2021年武义县疑似预防接种异常反应监测结果[J]. 预防医学, 2022, 34(11): 1167-1171,1177.
[9] 孙肖瑜, 郑晓春, 魏晶娇, 陈玲萍, 王志刚, 李万仓, 王婵敏. 2016—2020年温州市流行性乙型脑炎流行特征分析[J]. 预防医学, 2021, 33(9): 919-920.
[10] 林越东, 李峤, 覃青连, 颜星星, 成曼, 周红霞, 唐咸艳. 广西某医学院校女大学生接种HPV 疫苗知识、信念和行为调查[J]. 预防医学, 2021, 33(9): 955-957.
[11] 龚震宇, 龚训良. 世界卫生组织关于在社区暴发环境下接种肺炎球菌结合疫苗的附加意见书(摘译)[J]. 预防医学, 2021, 33(7): 755-756.
[12] 朱义雯, 邓桢, 巴观平, 刘勇, 陈玉丰. 基于创新扩散理论的人乳头瘤病毒疫苗接种行为分析[J]. 预防医学, 2021, 33(5): 457-461.
[13] 严波, 周倩意, 郑晓晖, 余昭锋, 鲁影, 刘紫瑜, 陈维清. 中国儿童家长疑似预防接种异常反应知晓率的Meta分析[J]. 预防医学, 2021, 33(3): 250-254.
[14] 罗美玲, 张英, 刘浩, 杨皓斌, 林希建. 长沙市儿童家长购买预防接种异常反应补充保险的影响因素分析[J]. 预防医学, 2020, 32(8): 774-777.
[15] 段良松, 李成华, 黄凯. 2011—2018年郴州市A群脑膜炎球菌多糖疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2020, 32(4): 402-404.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed